VivoSim Labs, Inc.
VIVS Healthcare Biotechnology
VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025. In the quarter to June 2026, revenue fell 51.4%, EPS grew 78.1% and free cash flow grew 17.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow VIVS
VivoSim Labs, Inc. (VIVS) EV/Sales
As of 16 October 2026, VivoSim Labs, Inc. (VIVS) trades at a EV/Sales of −7.4×. Over the past ten years it has ranged from −64.2× (June 2025) to 1,280× (January 2015); the current reading is higher than 6% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | −10.1× | — |
| FY2025 | −55.8× | — |
| FY2024 | 24.1× | 1,366.01% |
| FY2023 | 1.6× | 23.03% |
| FY2022 | 1.3× | (88.62%) |
| FY2020 | 11.7× | (51.95%) |
| FY2019 | 24.4× | 93.20% |
| FY2018 | 12.6× | (78.46%) |
| FY2017 | 58.6× | (34.75%) |
| FY2016 | 89.9× | (77.85%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 35.1× | — |
| Mar 2026 | −10.1× | — |
| Dec 2025 | 3.1× | (54.07%) |
| Sep 2025 | 6.6× | — |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AFMDQ Affimed N.V. compare | −19.2× |
| VIVS VivoSim Labs, Inc. | −7.4× |
| ONCO Onconetix, Inc. compare | −7.3× |
| DCOY Decoy Therapeutics Inc compare | −3.5× |
| ARAV ARAVIVE, INC compare | −0.4× |
| SLXN Silexion Therapeutics Corp compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | 0.6× |
| HCWB HCW Biologics Inc. compare | 1.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)